Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 25, Issue , 2014, Pages iii113-iii123

  Casali, Paolo G ^a   Blay, Jean Yves ^a   Bertuzzi, Alexia ^a   Bielack, Stefan ^a   Bjerkehagen, Bodil ^a   Bonvalot, Sylvie ^a   Boukovinas, Ioannis ^a   Bruzzi, Paolo ^a   Tos, Angelo Paolo Dei ^a   Dileo, Palma ^a   Eriksson, Mikael ^a   Fedenko, Alexander ^a   Ferrari, Andrea ^a   Ferrari, Stefano ^a   Gelderblom, Hans ^a   Grimer, Robert ^a   Gronchi, Alessandro ^a   Haas, Rick ^a   Hall, Kirsten Sundby ^a   Hohenberger, Peter ^a   Issels, Rolf ^a   Joensuu, Heikki ^a   Judson, Ian ^a   Cesne, Axel Le ^a   Litière, Saskia ^a   Martin Broto, Javier ^a   Merimsky, Ofer ^a   Montemurro, Michael ^a   Morosi, Carlo ^a   Picci, Piero ^a   Ray Coquard, Isabelle ^a   Reichardt, Peter ^a   Rutkowski, Piotr ^a   Schlemmer, Marcus ^a   Stacchiotti, Silvia ^a   Torri, Valter ^a   Trama, Annalisa ^a   Van Coevorden, Frits ^a   Van der Graaf, Winette ^a   Vanel, Daniel ^a   Wardelmann, Eva ^a   Bolle, Stephanie ^a   Capanna, Rodolfo ^a   Delaney, Thomas ^a   Doglietto, Francesco ^a   Fossati, Piero ^a   Jeys, Lee ^a   Kasper, Bernd ^a   Leithner, Andreas ^a   Norum, Ole Jacob ^a   Radaelli, Stefano ^a   Scheipl, Susanne ^a   Tamborini, Elena ^a   Uhl, Mathias ^a   Vleggert Lankamp, Carmen L A ^a   more..

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; METHOTREXATE; MURAMYL TRIPEPTIDE; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

AGE DISTRIBUTION; ARTICLE; BONE BIOPSY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CHONDROSARCOMA; CHORDOMA; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; EWING SARCOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; OSTEOCLASTOMA; OSTEOSARCOMA; PLEOMORPHIC BONE SARCOMA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SARCOMA; SEX DIFFERENCE; TREATMENT DURATION; BONE NEOPLASMS; HEALTH CARE PLANNING; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PROGNOSIS; STANDARDS;

BONE NEOPLASMS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASM STAGING; PROGNOSIS; SARCOMA; SOCIETIES, MEDICAL;

EID: 84911463658     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu256     Document Type: Article

References (95)

1. Stiller CA, Craft AW, Corazziari I. EUROCARE Working Group. Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur J Cancer 2001; 37: 760-766.
2. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res 2006; 21(Suppl 2): 58-63.
3. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002; 40-52.
4. Cotterill SJ, Parker L, Malcolm AJ et al. Incidence and survival for cancer in children and young adults in the North of England, 1968-1995: a report from the Northern Region Young Persons' Malignant Disease Registry. Br J Cancer 2000; 83: 397-403.
5. Bovée JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn P. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005; 6: 599-607.
6. van den Berg H, Kroon HM, Slaar A, Hogendoorn P. Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration 'PALGA'. J Pediatr Orthop 2008; 28: 29-35.
7. Hauben EI, Hogendoorn PCW. Epidemiology of primary bone tumors and economical aspects of bone metastases. In Heymann D (ed), Bone Cancer. Progression and Therapeutic Approaches, 1st edition. London: Academic Press 2009; 3-8.
8. Malhas AM, Grimer RJ, Abudu A et al. The final diagnosis in patients with a suspected primary malignancy of bone. J Bone Joint Surg Br 2011; 93: 980-983.
9. Grimer RJ, Briggs TW. Earlier diagnosis of bone and soft-tissue tumors. J Bone Joint Surg Br 2010; 92: 1489-1492.
10. Enneking WF. The issue of the biopsy. J Bone Joint Surg Am 1982; 64: 1119-1120.
11. Andreou D, Bielack SS, Carrle D et al. The influence of tumor- and treatment related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol 2011; 22: 1228-1235.
12. van den Berg H, Slaar A, Kroon HM et al. Results of diagnostic review in pediatric bone tumors and tumorlike lesions. J Pediatr Orthop 2008; 28: 561-564.
13. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am 1982; 64: 1121-1127.
14. Meyer JS, Nadel HR, Marina N et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group BoneTumor Committee. Pediatr Blood Cancer 2008; 51: 163-170.
15. WHO Classification of Tumors. In Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds), WHO Classification of Tumours of Soft Tissue and Bone. Lyon: IARC 2013.
16. Abdul-Karim FW, Bauer TW, Kilpatrick SE et al. Recommendations for the reporting of bone tumors. Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 2004; 35: 1173-1178.
17. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153: 106-120.
18. Sobin LH, Gospodarowicz MK, Wittekind CH (eds). TNM Classification of Malignant Tumors, 7th edition. Oxford: Wiley-Blackwell 2009.
19. Picci P, Vanel D, Briccoli A et al. Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. Ann Oncol 2001; 12: 1601-1604.
20. Benz MR, Tchekmedyian N, Eilber FC et al. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol 2009; 21: 345-351.
21. Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremityosteosarcoma: a systematic review. Eur J Surg Oncol 2009; 35: 1030-1036.
22. Leavey PJ, Collier AB. Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 2008; 8: 617-624.
23. Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
24. Picci P, Sangiorgi L, Rougraff BT et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12: 2699-2705.
25. Grimer RJ, Bielack S, Flege S et al. Periosteal osteosarcoma-a European review of outcome. Eur J Cancer 2005; 41: 2806-2811.
26. Cesari M, Alberghini M, Vanel D et al. Periosteal osteosarcoma: a single institution experience. Cancer 2011; 117: 1731-1735.
27. Bramer JA, Abudu AA, Grimer RJ et al. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur J Cancer 2007; 43: 1944-1951.
28. Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with high dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-8852.
29. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352.
30. Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
31. Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop 2006; 30: 445-451.
32. Bielack SS, Machatschek JN, Flege S, Jürgens H. Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother 2004; 5: 1243-1256.
33. Goorin AM, Schwartzentruber DJ, Devidas M et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for non metastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003; 21: 1574-1580.
34. Whelan J, Patterson D, Perisoglou M et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010; 54: 350-354.
35. Meyers PA, Schwartz CL, Krailo MD et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008; 26: 633-638.
36. Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. J Clin Oncol 2008; 26: 3103-3104.
37. van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol 1998; 27: 57-71.
38. van der Woude HJ, Bloem JL, Verstraete KL et al. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am J Roentgenol 1995; 165: 593-598.
39. Grimer RJ, Cannon SR, Taminiau AM et al. Osteosarcoma over the age of forty. Eur J Cancer 2003; 39: 157-163.
40. Kager L, Zoubek A, Potschger U et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-2018.
41. Ferrari S, Briccoli A, Mercuri M et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715.
42. Kempf-Bielack B, Bielack SS, Jurgens H et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-568.
43. Berger M, Grignani G, Giostra A et al. 153 Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann Oncol 2012; 23: 1899-1905.
44. Aurias A, Rimbaut C, Buffe D et al. Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors. Cancer Genet Cytogenet 1984; 12: 21-25.
45. Turc-Carel C, Philip I, Berger MP et al. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t (11;22)(q24;q12). Cancer Genet Cytogenet 1984; 12: 1-19.
46. Zoubek A, Pfleiderer C, Salzer-Kuntschik M et al. Variability of EWS chimaeric transcripts in Ewing tumors: a comparison of clinical and molecular data. Br J Cancer 1994; 70: 908-913.
47. Sorensen PH, Lessnick SL, Lopez-Terrada D et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6: 146-151.
48. Machado I, Noguera R, Pellin A et al. Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560 cases with FISH and RT-PCR. Diagn Mol Pathol 2009; 18: 189-199.
49. Cangir A, Vietti TJ, Gehan EA et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66: 887-893.
50. Bernstein ML, Devidas M, Lafreniere D et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457-a report from the Children's Oncology Group. J Clin Oncol 2006; 24: 152-159.
51. Bacci G, Ferrari S, Bertoni F et al. Prognostic factors in non metastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000; 18: 4-11.
52. Bacci G, Forni C, Longhi A et al. Long-term outcome for patients with non metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004; 40: 73-83.
53. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-3114.
54. Paulussen M, Ahrens S, Craft AW et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16: 3044-3052.
55. Pinkerton CR, Bataillard A, Guillo S et al. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer 2001; 37: 1338-1344.
56. Le Deley MC, Delattre O, Schaefer KL et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010; 28: 1982-1988.
57. van Doorninck JA, Ji L, Schaub B et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2010; 28: 1989-1994.
58. Schuck A, Ahrens S, Paulussen M et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003; 55: 168-177.
59. Bernstein M, Kovar H, Paulussen M et al. Ewing's sarcoma family of tumors: current management. Oncologist 2006; 11: 503-519.
60. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701.
61. Nesbit ME, Jr, Gehan EA, Burgert EO, Jr et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long term follow-up of the first intergroup study. J Clin Oncol 1990; 8: 1664-1674.
62. Paulussen M, Craft AW, Lewis I et al. Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26: 4385-4393.
63. Ferrari S, Sundby Hall K, Luksch R et al. Nonmetastatic Ewing family tumors: highdose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol 2011; 22: 1221-1227.
64. Shapeero LG, Vanel D. Imaging evaluation of the response of high-grade osteosarcoma and Ewing sarcoma to chemotherapy with emphasis on dynamic contrast-enhanced magnetic resonance imaging. Semin Musculoskelet Radiol 2000; 4: 137-146.
65. Ladenstein R, Pötschger U, Le Deley MC et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28: 3284-3291.
66. Haeusler J, Ranft A, Boelling T et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010; 116: 443-450.
67. Stahl M, Ranft A, Paulussen M et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011; 57: 549-553.
68. Ferrari S, del Prever AB, Palmerini E. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer 2009; 52: 581-584.
69. Wagner LM, McAllister N, Goldsby RE et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007; 48: 132-139.
70. Hunold A, Weddeling N, Paulussen M et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006; 47: 795-800.
71. Souhami RL, Tannock I, Hohenberger JC (eds) et al. Oxford Textbook of Oncology. Oxford: Oxford University Press 2002.
72. Pakos EE, Grimer RJ, Peake D et al. The 'other' bone sarcomas: prognostic factors and outcomes of spindle cell sarcomas of bone. J Bone Joint Surg Br 2011; 93: 1271-1278.
73. Eefting D, Schrage YM, Geirnaerdt MJ et al. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Am J Surg Pathol 2009; 33: 50-57.
74. Gelderblom H, Hogendoorn PC, Dijkstra SD et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13: 320-329.
75. Riedel RF, Larrier N, Dodd L et al. The clinical management of chondrosarcoma. Curr Treat Options Oncol 2009; 10: 94-106.
76. Geirnaerdt MJ, Hogendoorn PC, Bloem JL et al. Cartilaginous tumors: fast contrast-enhanced MR imaging. Radiology 2000; 214: 539-546.
77. Cesari M, Bertoni F, Bacchini P et al. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori 2007; 93: 423-427.
78. Dantonello TM, Int-Veen C, Leuschner I et al. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer 2008; 112: 2424-2431.
79. Dickey ID, Rose PS, Fuchs B et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am 2004; 86-A: 2412-2418.
80. Grimer RJ, Gosheger G, Taminiau A et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer 2007; 43: 2060-2065.
81. Noël G, Feuvret L, Ferrand R et al. Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas. Neurosurgery 2004; 55: 1252-1260.
82. Fox E, Patel S, Wathen JK et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research through Collaboration Study 003. Oncologist 2012; 17: 321.
83. Chawla S, Henshaw R, Seeger L et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14: 901-908.
84. Vujovic S, Henderson S, Presneau N et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006; 209: 157-165.
85. Rodallec MH, Feydy A, Larousserie F et al. Diagnostic imaging of solitary tumours of the spine: what to do and say. RadioGraphics 2008; 28: 1019-1041.
86. Di Maio S, Rostomily R, Sekhar LN. Current surgical outcomes for cranial base chordomas: cohort study of 95 patients. Neurosurgery 2012; 70: 1355-1360.
87. Yasuda M, Bresson D, Chibbaro S et al. Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients. Neurosurg Rev 2012; 35: 171-182.
88. Schulz-Ertner D, Karger CP, Feuerhake A et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007; 68: 449-457.
89. Fuchs B, Dickey ID, Yaszemski MJ et al. Operative management of sacral chordoma. J Bone Joint Surg Am 2005; 87: 2211-2216.
90. Stacchiotti S, Casali PG, Lo Vullo S et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 2010; 17: 211-219.
91. Clarke MJ, Dasenbrock H, Bydon A et al. Posterior-only approach for en bloc sacrectomy: clinical outcomes in 36 consecutive patients. Neurosurgery 2012; 71: 357-364; discussion 364.
92. Ares C, Hug EB, Lomax AJ et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first longterm report. Int J Radiat Oncol Biol Phys 2009; 75: 1111-1118.
93. Delaney TF, Liebsch NJ, Pedlow FX et al. Phase II study of high-dose photon/ proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009; 74: 732-739.
94. Stacchiotti S, Longhi A, Ferraresi V et al. A phase II study on imatinib in advanced chordoma. J Clin Oncol 2012; 30: 914-920.
95. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.